Xenetic Biosciences, Inc. – 2025 Annual Report (Form 10-K/A) Key Investor Highlights

Summary of the Filing

Xenetic Biosciences, Inc. has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment was made to provide the information required by Items 10 through 14 of Part III of Form 10-K, which were previously omitted pending the definitive proxy statement. The amendment includes updated executive, director, and beneficial ownership information, as well as details on compensation plans and auditor fees.

Key Points and Investor-Relevant Details

• Outstanding Shares:
  As of April 17, 2026, there were 2,391,056 shares of common stock outstanding. This is an update to the previously reported number and may affect calculations of ownership percentages and market capitalization.
• Stock Information:
  The company’s common stock (trading symbol XBIO) is listed on the Nasdaq Capital Market.
• Company Status:
  Xenetic Biosciences is not a well-known seasoned issuer, large accelerated filer, or an emerging growth company. It is categorized as a non-accelerated filer and a smaller reporting company.
• Compliance:
  The company confirms it has filed all required reports and submitted all interactive data files as required by SEC regulations.
• Internal Controls:
  No auditor attestation of management’s assessment of internal control over financial reporting was made under Section 404(b) of the Sarbanes-Oxley Act.
• Executive and Board Compensation:
  • CEO (James Parslow) received \$536,027 in total compensation for 2025, including a significant retention bonus. There were no stock or option awards vested or granted in 2025.
  • Former CEO received \$560,385 in compensation in 2025.
  • All current executive officers and directors as a group (7 persons) collectively own 180,145 shares, or 7.6% of the company.
  • Insider trading policy – The company has an insider trading policy covering directors, officers, employees, and designated consultants, which aims to ensure compliance with trading laws and listing standards.
  • Delinquent Section 16(a) Reports: Dr. Genkin has not yet filed his initial Form 3 after joining the Board, which could be relevant for transparency and regulatory compliance.
• Beneficial Ownership:
  • Renaissance Technologies, LLC holds 178,509 shares (7.8% ownership).
  • CLS Therapeutics Ltd. holds 147,500 shares (6.4% ownership).
• Equity Compensation Plans:
  • 114,163 securities to be issued upon exercise of outstanding options/warrants under approved plans, with a weighted average exercise price of \$11.17.
  • 137,985 securities remain available for future issuance under approved plans.
  • 1,459 securities to be issued under non-approved plans, with a high exercise price of \$548.40, indicating limited impact from these plans.
• Audit Fees and Financial Reporting:
  • Audit fees for 2025 amounted to \$165,000, covering the annual consolidated financial statement audit.
  • Audit-related fees in 2025 include costs for comfort letters related to a public offering in October 2025, which may indicate capital raising activities.
  • The company follows a policy requiring pre-approval of all audit and non-audit services by the Audit Committee.
• Corporate Governance:
  • The company’s Code of Business Conduct and Ethics applies to all employees, officers, and directors. Any material amendments or waivers will be disclosed on the company’s website.

Potential Price-Sensitive Information

• Executive Compensation: The CEO’s compensation saw a significant increase in 2025 due to a retention bonus. Investors may view this as a signal of leadership stability or as an area of concern regarding cost controls.
• Public Offering in October 2025: Audit-related fees include comfort letters for an underwritten public offering, hinting at capital raising or liquidity events that could affect share value.
• Change in Shares Outstanding: The updated shares outstanding figure (2,391,056) may affect dilution calculations and investor returns.
• Beneficial Ownership: Large shareholders, such as Renaissance Technologies and CLS Therapeutics, may influence company direction or share price through their holdings or trading activities.
• Section 16(a) Compliance: The missing Form 3 filing by a director may raise governance or compliance concerns.

Conclusion

The 10-K/A amendment provides updates on executive compensation, equity plans, share ownership, and audit fees. There are signals of recent capital raising activities, changes in leadership compensation, and updated shares outstanding figures. Investors should monitor these developments for potential impacts on share value and governance.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making investment decisions. All information is based on publicly available filings and may be subject to change.

View Xenetic Biosciences, Inc. Historical chart here